Academic Journal
The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes:a randomized crossover trial
| العنوان: | The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes:a randomized crossover trial |
|---|---|
| المؤلفون: | Hansen, Laura S, Gasbjerg, Lærke S, Brønden, Andreas, Dalsgaard, Niels B, Bahne, Emilie, Stensen, Signe, Hellmann, Pernille H, Rehfeld, Jens F., Hartmann, Bolette, Wever Albrechtsen, Nicolai J, Holst, Jens J, Vilsbøll, Tina, Knop, Filip K |
| المصدر: | Hansen , L S , Gasbjerg , L S , Brønden , A , Dalsgaard , N B , Bahne , E , Stensen , S , Hellmann , P H , Rehfeld , J F , Hartmann , B , Wever Albrechtsen , N J , Holst , J J , Vilsbøll , T & Knop , F K 2024 , ' The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes : a randomized crossover trial ' , European Journal of Endocrinology , vol. 191 , no. 2 , pp. 192-203 .... |
| سنة النشر: | 2024 |
| المجموعة: | University of Copenhagen: Research / Forskning ved Københavns Universitet |
| الوصف: | AIMS: Although metformin is widely used for treatment of type 2 diabetes (T2D), its glucose-lowering mechanisms remains unclear. Using the glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) antagonist exendin(9-39)NH2, we tested the hypothesis that postprandial GLP-1-mediated effects contribute to the glucose-lowering potential of metformin in T2D. METHODS: In a randomised, placebo-controlled, double-blind, crossover study, 15 individuals with T2D (median HbA1c 50 mmol/mol (6.7%), BMI 30.1 kg/m2, age 71 years) underwent, in randomised order, 14 days of metformin and placebo treatment, respectively. Each treatment period was preceded by 14 days without any glucose-lowering medicine and concluded by two 4-hour mixed meal tests performed in randomised order and separated by >24 hours with either continuous intravenous exendin(9-39)NH2 or saline infusion. RESULTS: Compared to placebo, metformin treatment lowered fasting plasma glucose (mean of differences (MD) 1.4 mmol/l×min (95% CI 0.8-2.0)) as well as postprandial plasma glucose excursions during both saline infusion (MD 186 mmol/l×min (95% CI 64-307)) and exendin(9-39)NH2 infusion (MD 268 mmol/l×min (95% CI 108-427)). The metformin-induced improvement in postprandial glucose tolerance was unaffected by GLP-1R antagonization (MD 82 mmol/l×min (95% CI -6,564-170)). Metformin treatment increased fasting plasma GLP-1 (MD 1.7 pmol/l×min (95% CI 0.39-2.9)) but did not affect postprandial GLP-1 responses (MD 820 pmol/l×min (95% CI -1,750-111)). CONCLUSIONS: Using GLP-1R antagonization, we could not detect GLP-1-mediated postprandial glucose-lowering effect of metformin in individuals with T2D. We show that two weeks of metformin treatment increases fasting plasma GLP-1, which may contribute to metformin's beneficial effect on fasting plasma glucose in T2D. TRIAL REGISTRATION: Clinicaltrials.gov NCT03246451. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1093/ejendo/lvae095 |
| الاتاحة: | https://researchprofiles.ku.dk/da/publications/the-role-of-glucagonlike-peptide-1-in-the-postprandial-effects-of-metformin-in-type-2-diabetes(d3232fcd-faac-48b7-aa55-f1c942a784e9).html https://doi.org/10.1093/ejendo/lvae095 |
| Rights: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.C73AC142 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/ejendo/lvae095 |
|---|